IL1F10

Across TCGA pan-cancer cohorts, IL1F10 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL1F10 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher IL1F10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL1F10 expression acts as an unfavorable survival marker.

ESCA, CHOL, and SARC are the cancer types where IL1F10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL1F10–ESCA (DFS)

Open the ESCA breakdown →